- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT -
- Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT -
- Conference call and webcast Tuesday, May 19, 6 p.m. PDT -
BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that an oral late-breaker presentation and two poster discussion presentations related to the company's pulmonology programs will be presented at the 2009 International Conference of the American Thoracic Society (ATS) in San Diego. In addition, the company will conduct a conference call and webcast to discuss the results of its Phase 3 CAPACITY program on Tuesday, May 19 at 6:00 p.m. PDT (9:00 p.m. EDT).
Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased that our Phase 3 CAPACITY program will be the subject of two significant sessions at this year's ATS meeting. Details of the CAPACITY results will be presented in a poster discussion session on the morning of Sunday, May 17. A more in-depth presentation of the efficacy and safety data from the two CAPACITY studies will be the subject of an oral late-breaker presentation on Tuesday, May 19. In addition, the results of a large study examining the predictors of mortality in patients with idiopathic pulmonary fibrosis (IPF) will be presented in a poster discussion session on Sunday, May 17. Among the independent predictors of mortality identified in the study was change in percent predicted forced vital capacity (FVC), the primary endpoint and a component of important secondary endpoints in our CAPACITY program."
The schedule of presentations at ATS related to InterMune's efforts in the research and development of new medicines for IPF are as follows:
|SOURCE InterMune, Inc.|
Copyright©2009 PR Newswire.
All rights reserved